Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Imtiaz A Samjoo

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Drugs in R&D|March 28, 2026
Response to "Treatment Outcomes with Lanadelumab Every Two Weeks and Garadacimab Are Very Similar in Patients with Hereditary Angioedema"Imtiaz A Samjoo
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|April 3, 2008
A neuromuscular approach to statin-related myotoxicitySteven K Baker, Imtiaz A Samjoo
Obesity (Silver Spring, Md.)|August 23, 2008
Effect of endurance exercise on hepatic lipid content, enzymes, and adiposity in men and womenMichaela C Devries, Imtiaz A Samjoo, Mazen J Hamadeh, et al.
Current Medical Research and Opinion|February 4, 2020
The impact of clinical heterogeneity on conducting network meta-analyses in transthyretin amyloidosis with polyneuropathyImtiaz A Samjoo, Elizabeth M Salvo, Diana Tran, et al.
Scientific Reports|March 18, 2015
Sex differences in skeletal muscle phosphatase and tensin homolog deleted on chromosome 10 (PTEN) levels: a cross-sectional studyM Constantine Samaan, Sonia S Anand, Arya M Sharma, et al.
Current Medical Research and Opinion|March 29, 2020
The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosisImtiaz A Samjoo, Evelyn Worthington, Anja Haltner, et al.
The Oncologist|October 19, 2024
Comparative efficacy and safety of talazoparib plus enzalutamide and other first-line treatments for metastatic castration-resistant prostate cancerElena Castro, Jenna Ellis, Samantha Craigie, et al.
The Oncologist|November 26, 2024
Systematic literature review and meta-analysis of health state utility values in metastatic castration-resistant prostate cancerElena Castro, Rhett Figliuzzi, Sarah Walsh, et al.
Clinical Genitourinary Cancer|July 11, 2024
Predicting Treatment Effects from Surrogate Endpoints in Historical Trials in First-Line Metastatic Castration-Resistant Prostate CancerImtiaz A Samjoo, Tim Disher, Elena Castro, et al.
Prostate Cancer and Prostatic Diseases|December 7, 2024
Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: a matching-adjusted indirect comparisonElena Castro, Di Wang, Sarah Walsh, et al.
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Drugs in R&D|March 28, 2026
Response to "Treatment Outcomes with Lanadelumab Every Two Weeks and Garadacimab Are Very Similar in Patients with Hereditary Angioedema"Imtiaz A Samjoo
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|April 3, 2008
A neuromuscular approach to statin-related myotoxicitySteven K Baker, Imtiaz A Samjoo
Obesity (Silver Spring, Md.)|August 23, 2008
Effect of endurance exercise on hepatic lipid content, enzymes, and adiposity in men and womenMichaela C Devries, Imtiaz A Samjoo, Mazen J Hamadeh, et al.
Current Medical Research and Opinion|February 4, 2020
The impact of clinical heterogeneity on conducting network meta-analyses in transthyretin amyloidosis with polyneuropathyImtiaz A Samjoo, Elizabeth M Salvo, Diana Tran, et al.
Scientific Reports|March 18, 2015
Sex differences in skeletal muscle phosphatase and tensin homolog deleted on chromosome 10 (PTEN) levels: a cross-sectional studyM Constantine Samaan, Sonia S Anand, Arya M Sharma, et al.
Current Medical Research and Opinion|March 29, 2020
The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosisImtiaz A Samjoo, Evelyn Worthington, Anja Haltner, et al.
The Oncologist|October 19, 2024
Comparative efficacy and safety of talazoparib plus enzalutamide and other first-line treatments for metastatic castration-resistant prostate cancerElena Castro, Jenna Ellis, Samantha Craigie, et al.
The Oncologist|November 26, 2024
Systematic literature review and meta-analysis of health state utility values in metastatic castration-resistant prostate cancerElena Castro, Rhett Figliuzzi, Sarah Walsh, et al.
Clinical Genitourinary Cancer|July 11, 2024
Predicting Treatment Effects from Surrogate Endpoints in Historical Trials in First-Line Metastatic Castration-Resistant Prostate CancerImtiaz A Samjoo, Tim Disher, Elena Castro, et al.
Prostate Cancer and Prostatic Diseases|December 7, 2024
Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: a matching-adjusted indirect comparisonElena Castro, Di Wang, Sarah Walsh, et al.
Pageof 5